Riskpilot← Back to searchSign inGet full accessCURE AS
ASActiveOrg 922537674Kalfarveien 37, 5022 BergenGrafisk og visuell kommunikasjonsdesign · NACE 74102Est. 20190 employees
Revenue 2022
NOK 18K
-99% vs 2021
EBITDA margin
-566.5%
+92% vs 2021
Equity ratio
-1910.2%
Financial strength
Net profit 2022
NOK -101K
+92% vs 2021
| Revenue | NOK 18K | -99% |
| EBITDA | NOK -101K | +92% |
| Net profit | NOK -101K | +92% |
| Total assets | NOK 81K | -91% |
| Equity | NOK -1,5M | -7% |
| Employees | 0 | — |
Legal name
CURE AS
Org number
922537674
Legal form
Aksjeselskap
NACE code
74102 · Grafisk og visuell kommunikasjonsdesign
Founded
26. mars 2019
Share capital
NOK 200 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Daglig leder og ett styremedlem i fellesskap.
Company purpose
Digitalt markedsbyrå med salg av tilhørende tjenester og varer.
Address
Kalfarveien 37, 5022 Bergen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue | 1 662 | 5 386 | 2 816 | 18 |
| Staff expenses | −1 004 | −1 432 | −1 594 | −16 |
| EBITDA | −779 | 570 | −1 331 | −101 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −779 | 570 | −1 331 | −101 |
| Net financials | 0 | −0 | −1 | −0 |
| Profit before tax | −778 | 570 | −1 332 | −101 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −778 | 570 | −1 332 | −101 |
| Item | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Total assets | 1 695 | 3 374 | 945 | 81 |
| Equity | −678 | −109 | −1 440 | −1 541 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 2 039 | 3 447 | 2 386 | 1 622 |
| Total debt | 2 039 | 3 447 | 2 386 | 1 622 |
EBITDA margin
-566.5%
This company
15.8%
Market median
-3685% vs market
20192022
Equity ratio
-1910.2%
This company
38.2%
Market median
-5101% vs market
20192022
Return on equity
-10086500.0%
This company
18.4%
Market median
-54818035% vs market
20192022
Net profit margin
-567.3%
This company
8.1%
Market median
-7104% vs market
20192022
Asset turnover
0.22×
This company
1.12×
Market median
-80% vs market
20192022
Debt / equity
1.05×
This company
0.62×
Market median
-69% vs market
20192022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Cure Holding As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Som Invest As
CURE AS Board members of CURE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Truls-Petter Bergh | Chief Executive Officer | 0 companies |
| Brage Istad Brenna-Lund | Board of Directors | 0 companies |
| Bendik Ådnøy Bergh | Board of Directors | 0 companies |
| Erik Windahl Olsen | Board of Directors | 0 companies |
| Stein Ove Molvik | Chairman | 0 companies |